SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: David Cathcart who wrote (1414)4/12/2002 3:15:23 PM
From: Biomaven  Read Replies (2) | Respond to of 1826
 
When they are confronted with new style drugs and technology where they don't have a 500 page manual and a file cabinet of similar cases THEY FREEZE UP.

Like they did with Gleevec? <g> (It was actually approved in just a few months).

But it is true that the FDA approval bar for a drug like Irofulven (particularly as a second-line drug) is unusually low.

I don't disagree that GNTA is a crap-shoot.

Peter


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News